{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-072612","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2023-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.482247+00:00","generated_at":"2026-06-07T07:46:40.377481+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"MEI Pharma adopts Sixth Amended and Restated Bylaws effective December 18, 2023","bullets":["Board designated at eight directors; amendments conform to revised DGCL.","Changes include updated meeting notice rules, adjourned meetings, record date.","Board may now designate any person (not just officers) to chair stockholder meetings.","Director removal standard aligned with DGCL and Certificate of Incorporation.","Administrative updates: gender-neutral terms, waiver by electronic transmission."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-072612","json":"https://secwatch.observer/filing/0000950170-23-072612.json","markdown":"https://secwatch.observer/filing/0000950170-23-072612.md","text":"https://secwatch.observer/filing/0000950170-23-072612.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000095017023072612/0000950170-23-072612-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000095017023072612/meip-20231218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T07:46:40.377481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ca12fef08a0e03a7da38813a851ac6e66adbd13f","claim":"Lite Strategy, Inc.: Amended and restated bylaws to align with DGCL, update meeting procedures, director count, removal standard, and gender-neutral terms (effective 2023-12-18).","evidence_excerpt":"On December 18, 2023, the Board of Directors (the Board) of MEI Pharma, Inc. (the Company) approved the Sixth Amended and Restated Bylaws of the Company (the Sixth A&R Bylaws), effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000095017023072612/0000950170-23-072612-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-12-18"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}